J Martin-Broto1, A Gutierrez2, X Garcia-Del-Muro3, J A Lopez-Guerrero4, J Martinez-Trufero5, L M de Sande6, N Lainez7, J Maurel8, A De Juan9, F Losa10, R Andres11, A Casado12, P G Tejido13, R Blanco14, J Carles15, J Bellmunt16, A Gomez-España17, R Ramos18, J Martinez-Serra19, A Llombart-Bosch20, A Poveda21. 1. Departments of Oncology and Hematology, Medical and Translational Hemato-Oncology Group, Hospital Universitario Son Dureta, Palma de Mallorca. Electronic address: javier.martin@ssib.es. 2. Departments of Oncology and Hematology, Medical and Translational Hemato-Oncology Group, Hospital Universitario Son Dureta, Palma de Mallorca. 3. Department of Oncology, Institut Català d'Oncologia, Barcelona. 4. Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia. 5. Department of Oncology, Hospital Miguel Servet, Zaragoza. 6. Department of Oncology, Complejo Hospitalario de León, Leon. 7. Department of Oncology, Hospital Virgen del Camino, Pamplona. 8. Department of Oncology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica de Enfermedades Hepáticas y Digestivas, Barcelona. 9. Oncology Department, Hospital de Valdecilla, Santander. 10. Department of Oncology, Hospital General, Hospitalet de Llobregat. 11. Department of Oncology, Hospital Clínico Lozano Blesa, Zaragoza. 12. Department of Oncology, Hospital Universitario San Carlos, Madrid. 13. Department of Oncology, Hospital San Pedro, Logroño. 14. Department of Oncology, Hospital Mutua de Terrassa, Terrassa. 15. Department of Oncology, Hospital del Mar, Barcelona. 16. Department of Oncology, Hospital Vall d'Hebron, Barcelona. 17. Department of Oncology, Hospital Reina Sofia, Córdoba. 18. Department of Pathology, Hospital Universitario Son Dureta, Palma de Mallorca. 19. Laboratory of Molecular Biology, Hospital Universitario Son Dureta, Palma de Mallorca. 20. Department of Pathology, Universidad de Valencia, Valencia. 21. Department of Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
Abstract
BACKGROUND: To assess whether deletions involving codons 557 and/or 558 (critical deletions) of exon 11 of KIT are relevant in the prognosis of relapse-free survival (RFS) in gastrointestinal stromal tumor (GIST) patients with a long follow-up. PATIENTS AND METHODS: A univariate and multivariate analysis for RFS were carried out on 162 localized GIST patients over the entire follow-up period and over the intervals 0-4 years and >4 years. Factors assessed among others were Fletcher/National Institutes of Health and Miettinen-Lasota/Armed Forces Institute of Pathology (M-L/AFIP) risk categories, critical deletions and non-deletion-type mutation (NDTM) within exon 11 of KIT. RESULTS: Multivariate analyses revealed that M-L/AFIP [relative risk (RR) 11.45, confidence interval (CI) 4.40-29.76, for the high-risk subgroup and RR 5.97, CI 2.09-17.06, for the intermediate subgroup] and critical deletions (RR 3.05, CI 1.59-5.85) were independent prognostic factors for RFS for the first 4 years and for the entire follow-up period. Beyond 4 years, the high-risk M-L/AFIP subgroup (RR 8.12, CI 1.48-44.4) and NDTM (RR 6.42, CI 1.17-35.12) were independent prognostic factors for RFS. The median follow-up was 84 months. CONCLUSION: Critical deletions represent a time-dependent prognostic factor limited to the first 4 years after surgery, which could help identify a subset with higher and earlier risk for relapse in GIST patients.
BACKGROUND: To assess whether deletions involving codons 557 and/or 558 (critical deletions) of exon 11 of KIT are relevant in the prognosis of relapse-free survival (RFS) in gastrointestinal stromal tumor (GIST) patients with a long follow-up. PATIENTS AND METHODS: A univariate and multivariate analysis for RFS were carried out on 162 localized GIST patients over the entire follow-up period and over the intervals 0-4 years and >4 years. Factors assessed among others were Fletcher/National Institutes of Health and Miettinen-Lasota/Armed Forces Institute of Pathology (M-L/AFIP) risk categories, critical deletions and non-deletion-type mutation (NDTM) within exon 11 of KIT. RESULTS: Multivariate analyses revealed that M-L/AFIP [relative risk (RR) 11.45, confidence interval (CI) 4.40-29.76, for the high-risk subgroup and RR 5.97, CI 2.09-17.06, for the intermediate subgroup] and critical deletions (RR 3.05, CI 1.59-5.85) were independent prognostic factors for RFS for the first 4 years and for the entire follow-up period. Beyond 4 years, the high-risk M-L/AFIP subgroup (RR 8.12, CI 1.48-44.4) and NDTM (RR 6.42, CI 1.17-35.12) were independent prognostic factors for RFS. The median follow-up was 84 months. CONCLUSION: Critical deletions represent a time-dependent prognostic factor limited to the first 4 years after surgery, which could help identify a subset with higher and earlier risk for relapse in GIST patients.
Authors: Christopher L Corless; Karla V Ballman; Cristina R Antonescu; Violetta Kolesnikova; Robert G Maki; Peter W T Pisters; Martin E Blackstein; Charles D Blanke; George D Demetri; Michael C Heinrich; Margaret von Mehren; Shreyaskumar Patel; Martin D McCarter; Kouros Owzar; Ronald P DeMatteo Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544
Authors: J Martin-Broto; V Martinez-Marín; C Serrano; N Hindi; J A López-Guerrero; R Ramos-Asensio; A Vallejo-Benítez; D Marcilla-Plaza; R González-Cámpora Journal: Clin Transl Oncol Date: 2016-12-09 Impact factor: 3.405
Authors: Kjetil Søreide; Oddvar M Sandvik; Jon Arne Søreide; Einar Gudlaugsson; Kjersti Mangseth; Hans Kristian Haugland Journal: Clin Transl Oncol Date: 2012-07-18 Impact factor: 3.405